Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate

Clinical Rheumatology

Volumn 32, Issue 11, 2013, Pages 1605-1612

  Fitzpatrick, Ray ^a   Scott, David Gi ^b   Keary, Ian ^c  

^a NEW CROSS HOSPITAL   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^c Strategen Ltd   (United Kingdom)

Author keywords

Biologic therapy; Continuation rates; Cost effectiveness; Methotrexate failure; Oral methotrexate; Rheumatoid arthritis; Subcutaneous methotrexate

Indexed keywords

ADALIMUMAB; ETANERCEPT; METHOTREXATE; RITUXIMAB;

ARTICLE; BIOLOGICAL THERAPY; CONTROLLED STUDY; COST CONTROL; COST MINIMIZATION ANALYSIS; DRUG COST; DRUG TOLERABILITY; DRUG USE; HUMAN; MAJOR CLINICAL STUDY; METHODOLOGY; NATIONAL HEALTH SERVICE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; UNITED KINGDOM;

ADMINISTRATION, ORAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; COST-BENEFIT ANALYSIS; HUMANS; INJECTIONS, SUBCUTANEOUS; METHOTREXATE; MODELS, ECONOMIC; RETREATMENT; TREATMENT OUTCOME;

EID: 84886247119     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2318-z     Document Type: Article

References (39)

1. National Collaborating Centre for Chronic Conditions (2009) Rheumatoid arthritis: national clinical guideline for management and treatment in adults. Royal College of Physicians of London
2. National Institute for Health and Clinical Excellence (2009) Rheumatoid arthritis. The management of rheumatoid arthritis in adults. http://www.nice.org.uk/nicemedia/pdf/CG79NICEGuideline.pdf. Accessed 30 April 2012
3. Smolen JS, Landewé R, Breedveld FC et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964-975. doi: 10.1136/ard.2009.126532
4. Jundt JW, Browne BA, Fiocco GP, Steele D, Mock D (1993) A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 20:1845-1849 (Pubitemid 24031585)
5. Brooks PJ, Spruill WJ, Parish RC, Birchmore D (1990) Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum 33:91-94 (Pubitemid 20040135)
6. Arthur V, Jubb R, Homer D (2002) A study of parenteral use of methotrexate in rheumatic conditions. J Clin Nurs 11:256-263 (Pubitemid 41749810)
7. National Institute for Health and Clinical Excellence (2007) Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. http://www.nice.org.uk/Guidance/TA130. Accessed 30 April 2012
8. National Audit Office (2009) Services for people with rheumatoid arthritis. http://www.nao.org.uk/publications/0809/rheumatoid-arthritis.aspx. Accessed 30 April 2012
9. Scott DL (2012) Biologics-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther 91:30-43. doi: 10.1038/clpt.2011.278
10. Deighton C, Hyrich K, Ding T et al (2010) BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology 49:1197-1199. doi: 10.1093/rheumatology/keq006a
11. Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M (2004) Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 31:645-648 (Pubitemid 38451248)
12. Braun J, Kästner P, Flaxenberg P, for the MC-MTX.6/RH Study Group et al (2008) Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 58:73-81. doi: 10.1002/art.23144
13. Rutkowska-Sak L, Rell-Bakalarska M, Lisowska B (2009) Oral vs. subcutaneous low-dose methotrexate treatment in reducing gastrointestinal side effects. Reumatologia 47:207-211
14. Mainman H, McClaren E, Heycock C, Saravanan V, Hamilton J, Kelly C (2010) When should we use parenteral methotrexate? Clin Rheumatol 29:1093-1098. doi: 10.1007/s10067-010-1500-9
15. Scott D, Claydon P, Ellis C, Buchan S (2012) A retrospective study of the effects of switching from oral to subcutaneous (SC) methotrexate (MTX): the Methotrexate Evaluation of Norwich Treatment Outcomes in RA (MENTOR) study. Poster no.: P221 presented at the British Society for Rheumatology, 1-3 May 2012, Glasgow, UK.
16. Crespo C, Brosa M, Galvan J et al (2010) Pharmacoeconomic analysis of Metoject® in the treatment of rheumatoid arthritis in Spain. Reumatol Clin 6:203-211. doi: 10.1016/j.reuma.2009.11.001
17. Fitzpatrick RW (2011) Optimal use of resources in treating oral methotrexate failure patients. Presented at a satellite symposium of the EULAR Annual European Congress of Rheumatology, London
18. Fitzpatrick RW (2012) Pharmacoeconomics of subcutaneous methotrexate. Hospital Pharmacy Europe 61:51-54
19. Hyrich KL, Watson KD, Lunt M, Symmons DP; British Society for Rheumatology Biologics Register (BSRBR) (2011) Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology 50:117-123. doi: 10.1093/rheumatology/keq209
20. National Institute for Health and Clinical Excellence (2010) Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor. http://www.nice.org.uk/guidance/ TA195/Guidance/pdf. Accessed 30 April 2012
21. Wiles N, Symmons DPM, Harrison B et al (1999) Estimating the incidence of rheumatoid arthritis. Trying to hit a moving target? Arthritis Rheum 42:1339-1346 (Pubitemid 30265590)
22. Office for National Statistics (2010) Based on national population estimates - current datasets. http://www.ons.gov.uk/ons/publications/re- reference-tables.html?edition=tcm%3A77-231847. Accessed 30 April 2012
23. Edwards CJ, Arden NK, Fisher D et al (2005) The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. Rheumatology (Oxford) 44:1394-1398 (Pubitemid 41631863)
24. Kiely P, Williams R, Walsh D, Young A, Early Rheumatoid Arthritis Network (2009) Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis: the ERAN cohort. Rheumatology (Oxford) 48:57-60. doi: 10.1093/rheumatology/ken406
25. Rachapalli SM, Williams R, Walsh DA, Young A, Kiely PD, Choy EH (2010) First-line DMARD choice in early rheumatoid arthritis - do prognostic factors play a role? Rheumatology (Oxford) 49:1267-1271. doi: 10.1093/rheumatology/ kep389
26. Rantalaiho V, Kautiainen H, Virta L, Korpela M, Möttönen T, Puolakka K (2011) Trends in treatment strategies and the usage of different disease-modifying anti-rheumatic drugs in early rheumatoid arthritis in Finland. Results from a nationwide register in 2000-2007. Scand J Rheumatol 40:16-21. doi: 10.3109/03009742.2010.486768
27. Katchamart W, Trudeau J, Phumethum V, Bombardier C (2009) Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 68:1105-1112. doi: 10.1136/ard.2008.099861
28. Choy EHS, Smith C, Doré CJ, Scott DL (2005) A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology 44:1414-1421 (Pubitemid 41631866)
29. British National Formulary 63. http://bnf.org/bnf/bnf/current/. Accessed 30 April 2012
30. NHS tariff 2010-2011 - outpatient attendances. http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-132654. Accessed 30 April 2012
31. NHS Clinical Knowledge Summaries. http://www.cks.nhs.uk/dmards. Accessed 30 April 2012
32. Lambert CM (2001) Medical therapy for rheumatoid arthritis - value for money? Rheumatology 40:961-964 (Pubitemid 32910434)
33. Singh JA, Furst DE, Bharat A et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 64:625-639. doi: 10.1002/acr.21641
34. Visser K, van der Heijde D (2009) Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 68:1094-1099. doi: 10.1136/ard.2008.092668
35. Bykerk VP, Akhavan P, Hazlewood GS et al (2012) Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol 39:1559-1582. doi: 10.3899/jrheum.110207
36. Wolfe F, Michaud K (2010) The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. Arthritis Res Ther 12:R35. doi: 10.1186/ar2944
37. Staples MP, March L, Lassere M, Reid C, Buchbinder R (2011) Health-related quality of life and continuation rate on first-line anti-tumour necrosis factor therapy among rheumatoid arthritis patients from the Australian Rheumatology Association Database. Rheumatology (Oxford) 50:166-175. doi: 10.1093/rheumatology/keq322
38. National Rheumatoid Arthritis Society (2010) The economic burden of rheumatoid arthritis. http://www.nras.org.uk/includes/documents/cm-docs/2010/e/ 1-economic-burden-of-ra-final-30-3-10.pdf. Accessed 30 April 2012
39. Striesow F, Brandt A (2012) Preference, satisfaction and usability of subcutaneously administered methotrexate for rheumatoid arthritis or psoriatic arthritis: results of a postmarketing surveillance study with a high-concentration formulation. Ther Adv Musculoskelet Dis 4:3-9. doi: 10.1177/1759720X11431004